Circulating levels of five proglucagon-derived peptides in response to intravenous or oral glucose or lipids and to a mixed-meal in subjects with normal weight, overweight, and obesity

What Was Tested

The paper reports a study of Glucagon and Oxyntomodulin, published as a clinical trial.

Proglucagon-derived peptides (PGDPs) secreted by the gut and pancreas play a major role in metabolism.

The researchers measured concentrations of five PGDPs in response to per os (PO) or intravenous (IV) glucose or lipid intake and a mixed meal test (MMT) consumed by subjects with normal weight, overweight or obesity.

Why It Was Studied

Study 1 has the NCT01520454 and the NCT04888325 number in ClinicalTrials.gov.

Study 2 has the number NCT01495754 in ClinicalTrials.gov.

Who Took Part

The abstract describes 32 subjects taking part.

GLP-1, oxyntomodulin and glicentin (gut-secreted PGDPs) and glucagon and MPGF (pancreas-secreted PGDPs) were assessed in: (a) 32 subjects receiving PO or IV glucose, lipids or water over 6 h, (b) 33 subjects with normal weight, overweight or obesity who consumed a MMT.

What Was Measured

PubMed files the paper under topics including Glicentin, Glucagon, Glucagon-Like Peptide 1, Glucose, Lipids, Obesity and Overweight.

The authors tagged it with the keywords Diabetes, GLP-1, MPGF, NAFLD, NASH and Oxyntomodulin.

What This Means in Plain Language

This is a clinical trial of Glucagon and Oxyntomodulin in 32 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2022 (Clinical nutrition (Edinburgh, Scotland)), a journal based in England.

More context: the Glucagon compound page and the Oxyntomodulin compound page, all human trials.